3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort

Godin, O.; Boyer, Laurent; Chéreau, Isabelle; Étain, Bruno; Llorca, Pierre‐Michel; Meynier, André; Andrieu-Haller, C.; Aouizerate, Bruno; Berna, Fabrice; Blanc, Olivier; Bourguignon, Erika; Capdevielle, Delphine; Chéreau-Boudet, I.; Clauss-Kobayashi, J.; Coulon, Nathalie; d’Amato, Thierry; Dassing, R.; Dorey, Jean‐Michel; Dubertret, Caroline; Esselin, A.; Fond, Guillaume; Gabayet, Franck; Jarroir, M.; Lacelle, D.; Lançon, C.; Laouamri, H.; Leboyer, Marion; Leignier, Sylvain; Llorca,; Mallet, J.; Metairie, E.; Michel, Tanja Maria; Misdrahi, D.; Passerieux, C.; Petrucci, J.; Pignon, Baptiste; Peri, P.; Portalier, C.; Rey, Romain; Román, C.; Schorr, Benoît; Schurhoff, F.; Szöke, Andreı̈; Tessier, A.; Urbach, M.; Wachiche, G.; Zinetti-Bertschy, A.

doi:10.1016/j.pnpbp.2022.110641

Cited by 4 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No statistically significant association was found between antipsychotic characteristics (number received, class of antipsychotic and route of administration) with the prevalence of MetS. This is similar to other studies like Godin et al . (2023) who found no association between the number of antipsychotics and MetS in schizophrenia patients in France as well as Correll et al , (2011), Hammoudeh et al .…”

Section: Discussionsupporting

confidence: 90%

Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders

Abdel Aziz,

Mohd Ahmed,

Stip

et al. 2024

International Clinical Psychopharmacology

View full text Add to dashboard Cite

The risk of metabolic syndrome (MetS) has been attributed to antipsychotic use in psychiatric patients. To date, there is limited data on the relationship between antipsychotic polypharmacy and MetS in patients with schizophrenia, schizoaffective disorder and bipolar disorder. Therefore, we aimed to investigate the rate of MetS in patients with these disorders receiving antipsychotic monotherapy and polypharmacy. We conducted a cross-sectional study on patients seen between January 2017 and December 2020, collecting data on the class, type, route of administration and number of antipsychotics received. We used the American Association of Clinical Endocrinology criteria to diagnose MetS. We included 833 subjects of whom 573 (68.8%) received antipsychotic monotherapy and 260 (31.2%) received polypharmacy. Overall, 28.6% (N = 238) had MetS with no statistical difference between the two groups. Diastolic blood pressure and receiving olanzapine were significant predictors for developing MetS. In conclusion, our study found no significant difference in the rate of MetS between antipsychotic monotherapy and polypharmacy. A number of variables were significant predictors for MetS. Our findings were consistent with other studies and warrant the need for careful choice of antipsychotics and regular screening and management of abnormal metabolic parameters.

show abstract